Metformin in Combination with Progesterone Improves the Pregnancy Rate for Patients with Early Endometrial Cancer

Feng Yuan, Ying Hu, Xi Han, and Qiumin Li

Department of Obstetrics, Shaanxi Provincial People’s Hospital, Xi’an, China

Correspondence should be addressed to Qiumin Li; ryddm2022@163.com

Received 20 May 2022; Revised 14 June 2022; Accepted 21 June 2022; Published 6 July 2022

Objective. To study the therapeutic effects of metformin in combination with medroxyprogesterone in the early endometrial cancer patients with fertility requirements. A total of 120 patients with early endometrial cancer admitted to and treated in our hospital were enrolled and evenly assigned into two groups according to different therapeutic regimens, namely, metformin group (metformin combined with medroxyprogesterone acetate) and control group (medroxyprogesterone acetate alone). The objective response rate (ORR) and disease control rate (DCR) were 71.7% (43/60) and 90.0% (54/60) in the metformin group and 53.3% (32/60) and 78.3% (47/60) in the control group, respectively. Adverse reactions such as gastrointestinal reaction, headache, and insomnia were mainly observed in patients. The body mass index (BMI) declined from \((34.43 \pm 4.34)\) kg/m\(^2\) to \((24.77 \pm 2.39)\) kg/m\(^2\) in the metformin group and from \((33.37 \pm 4.49)\) kg/m\(^2\) to \((31.28 \pm 3.55)\) kg/m\(^2\) in the control group after treatment. After treatment, serum levels of vascular endothelial growth factor (VEGF), angiotensin-2 (Ang-2), carbohydrate antigen 125 (CA125), and CA19-9 in the metformin group were significantly lower than those in the control group \((P < 0.005, P < 0.001, P = 0.002, \text{and} P < 0.001)\). During follow-up, the pregnancy rate was 81.7% (49/60) in the metformin group and 61.7% (37/60) in the control group, and the former was prominently higher than the latter \((P = 0.025)\). Metformin in combination with progesterone is effective in treating early endometrial cancer patients with fertility requirements, which significantly reduced the BMI of patients and increased the pregnancy rate after treatment.

1. Introduction

Endometrial cancer, one of the most common cancers of female reproductive system, accounts for about 7% of malignant tumors in females. Its incidence rate rises obviously in females aged below 40 years old in recent years, which is about 2–14% and increasing year by year [1]. Among such patients, 70% are nulliparous, so preserving the fertility function is of importance. Surgical resection is effective in the treatment of endometrial cancer, whose standard surgical approach is total hysterectomy + bilateral salpingo-oophorectomy, as well as lymph node dissection according to the clinical stage of patients. As a result, patients will permanently lose fertility [2].

Progesterone therapy is a therapeutic method most commonly used in clinic to preserve the fertility of patients. However, adverse reactions including progesterone resistance, thrombosis, and weight gain are observed with increasing application in clinical practice, affecting the treatment efficacy and compliance of patients [3, 4]. Metformin, a first-line drug for the treatment of diabetes, has been proven in many studies to be able to reduce the incidence rate, progression, and mortality rate of different human cancers, including EC [5]. Besides, previous evidence has demonstrated that metformin can increase progesterone sensitivity and improve progesterone resistance [6–9]. In the present research, the therapeutic effect of metformin in combination with progesterone in treating early endometrial cancer with fertility requirements was investigated, hoping to offer a basis for clinical research.

2. Materials and Methods

2.1. General Data. The clinical data of 120 patients with early endometrial cancer admitted to and treated in our hospital
were collected (the trial registration number: ChiCTR 1800020281) (Table 1). The inclusion criteria were set as follows:

1. Endometrioid well-differentiated adenocarcinoma diagnosed by histopathological examination after operation.
2. Patients with involved myometrium <1/2 and no extra-uterine lesions and lymph node metastasis by MRI.
3. Those who were aged <40 years old, nulliparous, and still had the willingness to bear children.
4. Those with estrogen-dependent and progesterone receptor (PR)-positive endometrial cancer.

The exclusion criteria were as follows:

1. Those who received other anti-tumor therapy were excluded.
2. Patients with severe heart, lung, liver, and kidney dysfunction, coagulation dysfunction, immune system disorders, or infectious diseases.
3. Patients with other malignant tumors.
4. Patients with abnormal neurological function.

The enrolled patients were divided into two groups according to different therapeutic regimens, namely, metformin group (metformin combined with medroxyprogesterone acetate, n = 60) and control group (medroxyprogesterone acetate alone, n = 60). Written signed informed consent was obtained from each patient before the study. This study was approved by the ethical committee of our hospital.

2.2. Therapeutic Methods. Patients in the control group took medroxyprogesterone acetate dispersible tablets (manufactured by Nanjing Cuccess Pharmaceutical Co., Ltd., Nanjing, China) orally at 0.4–0.8 g/d. In the metformin group, metformin (manufactured by Changzhou Pharmaceutical Factory Co., Ltd., Changzhou, China) was administrated orally (0.5 g/time, 3 times/d) in addition to the treatment in the control group. During continuous treatment, the clinical symptoms of patients in the two groups were closely observed. Administration was stopped when no residual disease was found. Patients could get pregnant only after 3 months of drug withdrawal.

2.3. Observation Indexes. The following indicators were calculated: complete remission (CR): lesions disappeared, with atrophy of endometrial glands and decidua response in the stroma, partial remission (PR): there were residues of hyperplastic endometrium, without atypical cell residues, stable disease (SD): histopathological examination results were consistent with those before treatment, and progressive disease (PD): myometrial infiltration was deepened or metastasis appeared. Objective response rate (ORR) = (CR + PR)/total number of cases × 100%; disease control rate (DCR) = (CR + PR + SD)/total number of cases × 100%.

The levels of tumor markers, including vascular endothelial growth factor (VEGF), angiotensin-2 (Ang-2), carbohydrate antigen (CA) 125, and CA19-9, were evaluated. Besides, the body mass index (BMI) of patients was also analyzed, and the incidence rate of adverse reactions such as gastrointestinal reactions, insomnia, and headache was compared between the two groups of patients.

Besides, the successful pregnancy rate, pregnancy status, and pregnancy outcome of patients in the two groups were followed up and recorded.

2.4. Statistical Analysis. SPSS 19.0 software (IBM, Armonk, NY, USA) was used for statistical analyses. All quantitative data were expressed as mean ± standard deviation. Student’s t-test was employed for comparing the variables before and after treatment. Percentage (%) was used to express the enumeration data, and the chi-square test was used for data analysis. A significant difference was set at P < 0.05.

3. Results

3.1. Comparison of Clinical Efficacy in Patients. The efficacy was assessed after treatment of all patients. The ORR and DCR were 71.7% (43/60) and 90.0% (54/60) in the metformin group and 53.3% (32/60) and 78.3% (47/60) in the control group, respectively. The ORR was remarkably higher in the metformin group than the control group (P = 0.038), whereas the DCR had no statistically significant difference (P = 0.132) (Table 2).

3.2. Evaluation of Adverse Reactions. Adverse reactions such as gastrointestinal reactions, headaches, and insomnia were mainly observed in patients. There were 8 (13.3%) and 5 (8.3%) cases of gastrointestinal reactions, 6 (10.0%) and 6 (10.0%) cases of headache, 5 (8.3%) and 5 (8.3%) cases of insomnia in the metformin group and control group, respectively.

3.3. Comparisons of BMI and Serum VEGF, Ang-2, CA125, and CA19-9 Levels. The BMI declined from (34.43 ± 4.34) kg/m² to (24.77 ± 2.39) kg/m² in the metformin group and from (33.37 ± 4.49) kg/m² to (31.28 ± 3.55) kg/m² in the control group after treatment. The serum VEGF, Ang-2, CA125, and CA19-9 levels displayed no statistically significant differences (P = 0.299, P = 0.580, P = 0.376, and P = 0.377). After treatment, such levels declined in both groups (VEGF: (482.31 ± 23.67) ng/L and (277.97 ± 21.89) ng/L to (287.63 ± 25.85) ng/L and (302.51 ± 30.43) ng/L, Ang-2: (1.47 ± 0.40) μg/L and (1.51 ± 0.39) μg/L to (0.39 ± 0.09) μg/L and (0.45 ± 0.11) μg/L, CA125: (53.03 ± 6.11) U/mL and (52.08 ± 5.58) U/mL to (28.78 ± 3.03) U/mL and (30.29 ± 2.21) U/mL, and CA19-9: (22.82 ± 1.96) kU/L and (22.49 ± 2.11) kU/L to (10.47 ± 1.08) kU/L and (12.63 ± 3.05) kU/L) (Figure 1).

3.4. Pregnancy Outcomes. Results showed that the pregnancy rate was 81.7% (49/60) in the metformin group and
improve the effect of conservative treatment to some extent. The study findings have shown that metformin can be applied by researchers in the conservative treatment of endometrial cancer. In recent years, metformin, an insulin sensitizer, has been applied in patients with metabolic syndromes. Studies have manifested that obesity and insulin resistance are related factors for the high recurrence rate and long duration of conservative treatment of endometrial cancer [11, 12]. For this reason, alleviating obesity, insulin resistance, and other metabolic syndromes in patients will be a new strategy for the conservative treatment of endometrial cancer. In recent years, metformin, an insulin sensitizer, has been applied in researchers in the conservative treatment of endometrial cancer. The study findings have shown that metformin can improve the effect of conservative treatment to some extent [13, 14].

A phase II clinical trial conducted by Mitsuhashi et al. in 2015, in which 36 patients with atypical endometrial hyperplasia/endometrial cancer (stage I, G1) were treated with MPA in combination with metformin for 24–36 weeks, reported that CR is found in 81% (29/36) of patients within 36 weeks, with a median follow-up of 38 months, and recurrence is observed in only 3 patients [15]. It was discovered in another study where the long-term efficacy of MPA combined with metformin conservative treatment was evaluated that the 12 and 18-month CR rates are 90% and 97%, respectively, with a median follow-up of 57 months, the recurrence rate is only 13%, and more benefits are obtained by obese patients from metformin-based combined therapy. It is probably because that metformin suppresses the secretion of adipokines, the driving factors for the increased obesity-induced risk of endometrial cancer, from adipocytes [16].

To find out whether metformin in combination with progesterone has a better therapeutic effect than progesterone alone, a study was conducted on 120 patients with early endometrial cancer. The results uncovered that the 16-week CR rate is higher in metformin + MA group than that in MA group. It was found through sub-group stratified analysis that patients with atypical dysplasia benefit more from metformin: the 16-week CR rate in metformin+MA group is almost twice that in MA group. Additionally, obese and insulin-sensitive patients also benefit from it [17]. However, a recent study reported that the recurrence rate shows no statistically significant difference between metformin combined with progesterone and progesterone alone (17% vs. 25%, P = 0.484). In the above-mentioned study, the BMI of patients is higher in metformin treatment group than that in control group (P = 0.042), and the dose of metformin is 500–1,000 mg. The insufficient dose of metformin and the heterogeneity of BMI between treatment groups may have some influence on the results of the study, so further research should be carried out for verification [18]. A meta-analysis by Chae-Kim et al. demonstrated that the combination therapy of progesterone and metformin is associated with lower relapse rates and similar remission, clinical pregnancy, and live birth rates for reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer [19]. Existing studies have manifested that metformin improves the remission rate and reduces the recurrence rate of conservatively treated patients to some extent. The results of this study revealed that the ORR was significantly higher in the metformin group than that in the control group, suggesting that metformin in combination with progesterone gets better therapeutic results than progesterone alone in patients with endometrial cancer.

### Table 1: Demographic characteristics of the patients in the 2 groups.

| Indicators                  | Metformin group (n = 60) | Control group (n = 60) | P value |
|-----------------------------|--------------------------|------------------------|---------|
| Age (years)                 | 33.73 ± 7.47             | 35.12 ± 8.41           | 0.257   |
| BMI (kg/m²)                 | 34.43 ± 4.24             | 33.37 ± 4.49           | 0.368   |
| Irregular menstruation (%)  | 38 (63.3%)               | 43 (71.7%)             | 0.563   |
| Course of disease (months)  | 10.3 ± 3.3               | 10.8 ± 3.6             | 0.437   |
| PCOS (%)                    | 21 (35.0%)               | 18 (30.0%)             | 0.578   |
| Insulin resistance (%)      | 19 (31.7%)               | 17 (28.3%)             | 0.444   |

PCOS: polycystic ovary syndrome.

### Table 2: Analysis of the therapeutic effects in patients of the two groups.

| Indicators                  | Metformin group (n = 60) | Control group (n = 60) | P value |
|-----------------------------|--------------------------|------------------------|---------|
| Complete response (CR)      | 16 (26.7%)               | 12 (20.0%)             |         |
| Partial response (PR)       | 27 (45.0%)               | 20 (33.3%)             |         |
| Stable disease (SD)         | 11 (18.3%)               | 15 (25.0%)             |         |
| Progressive disease (PD)    | 6 (10.0%)                | 13 (21.7%)             |         |
| ORR (CR + PR)               | 43 (71.7%)               | 32 (53.3%)             | 0.038   |
| DCR (CR + PR + SD)          | 54 (90.0%)               | 47 (78.3%)             | 0.132   |
Usually, conservative treatment with progesterone is adopted to alleviate tumor progression, conducive to pregnancy. The meta-analysis by Koska et al. showed that the pregnancy rate is 32% (111/351) after conservative treatment of endometrial cancer, implying that the traditional progesterone therapy leads to a poor pregnancy outcome. Hence, discovering new strategies to change this situation is urgent [20]. Considering that patients with endometrial cancer often suffer from infertility factors like obesity, polycystic ovary syndrome, and ovulation disorders, relieving the abnormal metabolism of their body may be a new direction for treatment. Research shows that metformin can attenuate ovulation disorders and promote pregnancy by improving the insulin resistance, glucose intolerance, and other metabolic status of patients with polycystic ovary syndrome [21]. In recent years, the application of metformin in the conservative treatment of endometrial cancer has been widely studied, and the results revealed that metformin is able to improve the pregnancy outcomes of patients. A study by Mitsuhashi et al. reported that CR is achieved through treatment with metformin combined with MPA, 50% (8/16) of early endometrial cancer patients who tried to get pregnant (16/29) are successfully pregnant, and the live birth rate is 37.5% [10]. It was found in another retrospective study that the overall pregnancy rate is 61% (19/31) after metformin combined with progesterone conservative treatment. The table below shows the evaluation of the pregnancy outcomes.

### Table 3: Evaluation of the pregnancy outcomes of the patients.

| Index                  | Metformin group (n = 60) | Control group (n = 60) | P value |
|------------------------|--------------------------|------------------------|---------|
| Pregnancy rate (%)     | 49 (81.7%)               | 37 (61.7%)             | 0.025   |
| Natural pregnancy      | 33 (67.3%)               | 23 (62.2%)             |         |
| ART pregnancy          | 16 (32.7%)               | 14 (37.8%)             |         |
| Pregnancy outcome      |                          |                        | 0.752   |
| Abortion               | 4 (8.2%)                 | 4 (10.8%)              |         |
| Premature delivery     | 8 (16.3%)                | 7 (18.9%)              |         |
| Term delivery          | 37 (75.5%)               | 26 (70.3%)             |         |

ART: assisted reproductive technology.

![Figure 1: Evaluation of the serum markers of the patients in the 2 groups: VEGF (a), Ang-2 (b), CA125 (c), and CA19-9 (d) (*p < 0.05).](image-url)
treatment, and the live birth rate is 45% (14/31) [16]. According to a recent prospective randomized controlled trial by Yang et al., the pregnancy rate is 51.8% in metformin + MA group (n = 37) and 48.4% in MA group (n = 31) [17]. The above findings indicate that the application of metformin improves the pregnancy rate of patients to a certain extent. It was found in this study that during follow-up, the pregnancy rate was significantly higher in the metformin group than that in the control group (81.7% vs. 61.7%, P = 0.025), and the metformin group also had a higher proportion of natural pregnancy than the control group, but the difference was of no statistical significance. It implies that metformin improves the pregnancy outcome of patients to some extent. The main novelty of the present study was that the patients enrolled in this research were evaluated comprehensively, including the clinical efficacy, adverse reactions, tumor marker levels, pregnancy rate, and abortion results. However, limitations also existed in this study. The limited sample size, short follow-up time, and comprehensive follow-up content might lead to the biased conclusions. Prospective clinical research data with rigorous design, high reliability, and large sample size are needed to support the conclusions drawn in this study in the future.

5. Conclusion

Metformin in combination with progesterone has exact effects in treating early endometrial cancer patients with fertility requirements, which is capable of significantly decreasing the BMI of patients and elevating the pregnancy rate after treatment.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] K. Moore and M. A. Brewer, “Endometrial cancer: is this a new disease?” Am Soc Clin Oncol Educ Book, vol. 37, pp. 435–442, 2017.

[2] G. Trojano, C. Olivieri, R. Tinelli, G. R. Damiani, A. Pellegrino, and E. Cicinelli, “Conservative treatment in early stage endometrial cancer: a review,” Acta BioMedica, vol. 90, no. 4, pp. 405–410, 2019.

[3] A. Gompel, “Progesterone and endometrial cancer,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 69, pp. 95–107, 2020.

[4] T. J. Cade, M. A. Quinn, R. M. Rome, and D. Neesham, “Long-term outcomes after progestogen treatment for early endometrial cancer,” The Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 53, no. 6, pp. 566–570, 2013.

[5] A. Gadducci, N. Biglia, R. Tana, S. Cosio, and M. Gallo, “Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning,” Critical Reviews in Oncology, vol. 105, pp. 73–83, 2016.

[6] Y. Jiang, X. Chen, Y. Wei, Y. Feng, W. Zheng, and Z. Zhang, “Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression,” Biomedicine & Pharmacotherapy, vol. 113, p. 108712, 2019.

[7] S. De Rocco, D. Bucal, L. Oronzii et al., “Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer and atypical hyperplasia: a systematic review and meta-analysis,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 273, pp. 90–97, 2022.

[8] T. Y. Lee, U. E. Martinez-Outschoorn, R. J. Schilder et al., “Metformin as a therapeutic target in endometrial cancers,” Frontiers in Oncology, vol. 8, p. 341, 2018.

[9] K. Garg and R. A. Soslow, “Endometrial carcinoma in women aged 40 years and younger,” Archives of Pathology & Laboratory Medicine, vol. 138, no. 3, pp. 335–342, 2014.

[10] A. Mitsuhashi and M. Shozu, “New therapeutic approaches for the fertility-sparing treatment of endometrial cancer,” Journal of Obstetrics and Gynaecology Research, vol. 46, no. 2, pp. 215–222, 2020.

[11] J. Y. Park, D. Y. Kim, J. H. Kim et al., “Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KOGG 2002),” European Journal of Cancer, vol. 49, no. 4, pp. 868–874, 2013.

[12] B. Yang, L. Xie, H. Zhang et al., “Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients,” J Gynecol Oncol, vol. 29, no. 3, p. e35, 2018.

[13] C. G. Meireles, S. A. Pereira, L. P. Valadares et al., “Effects of metformin on endometrial cancer: systematic review and meta-analysis,” Gynecologic Oncology, vol. 147, no. 1, pp. 167–180, 2017.

[14] N. Mu, T. Xu, M. Gao et al., “Therapeutic effect of metformin in the treatment of endometrial cancer,” Oncology Letters, vol. 20, no. 5, p. 156, 2020.

[15] A. Mitsuhashi, Y. Sato, T. Kiyokawa, M. Koshizaka, H. Hanaoka, and M. Shozu, “Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer,” Annals of Oncology, vol. 27, no. 2, pp. 262–266, 2016.

[16] A. Mitsuhashi, Y. Habu, T. Kobayashi et al., “Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients,” J Gynecol Oncol, vol. 30, no. 6, p. e90, 2019.

[17] B. Y. Yang, Y. Gulinazi, Y. Du et al., “Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 127, no. 7, pp. 848–857, 2020.

[18] S. Acosta-Torres, T. Murdock, R. Matsumo et al., “The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: little impact
on response and low live-birth rates,” Gynecologic Oncology, vol. 157, no. 2, pp. 348–356, 2020.

[19] J. Chae-Kim, G. Garg, L. Gavrilova-Jordan et al., “Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis,” International Journal of Gynecological Cancer, vol. 31, no. 12, pp. 1499–1505, 2021.

[20] M. Koskas, J. Uzan, D. Luton, R. Rouzier, and E. Darai, “Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis,” Fertility and Sterility, vol. 101, no. 3, pp. 785–794.e3, 2014.

[21] A. Sharpe, L. C. Morley, T. Tang, R. J. Norman, and A. H. Balen, “Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome,” Cochrane Database of Systematic Reviews, vol. 12, Article ID D13505, 2019.